Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 18.5
(0.11%)
HKD 18.5
(0.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -18.13 Billion CNY | -36.97% |
| 2022 | -13.23 Billion CNY | -21.73% |
| 2021 | -10.87 Billion CNY | -159.39% |
| 2020 | -4.19 Billion CNY | 49.06% |
| 2019 | -8.22 Billion CNY | -649.2% |
| 2018 | -1.09 Billion CNY | -243.32% |
| 2017 | -319.93 Million CNY | -37.26% |
| 2016 | -233.07 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -21.7 Billion CNY | 0.0% |
| 2023 Q2 | -12.36 Billion CNY | 0.0% |
| 2023 Q4 | -18.13 Billion CNY | 0.0% |
| 2023 FY | -18.13 Billion CNY | -36.97% |
| 2022 Q4 | -13.23 Billion CNY | 0.0% |
| 2022 FY | -13.23 Billion CNY | -21.73% |
| 2022 Q2 | -12.84 Billion CNY | 0.0% |
| 2021 Q4 | -10.87 Billion CNY | 0.0% |
| 2021 FY | -10.87 Billion CNY | -159.39% |
| 2021 Q2 | -10.47 Billion CNY | 0.0% |
| 2020 FY | -4.19 Billion CNY | 49.06% |
| 2020 Q4 | -4.19 Billion CNY | 0.0% |
| 2020 Q2 | -5.46 Billion CNY | 0.0% |
| 2019 FY | -8.22 Billion CNY | -649.2% |
| 2019 Q4 | -8.22 Billion CNY | 0.0% |
| 2019 Q2 | -1.01 Billion CNY | 0.0% |
| 2018 FY | -1.09 Billion CNY | -243.32% |
| 2018 Q3 | -1.09 Billion CNY | 0.0% |
| 2018 Q4 | -1.09 Billion CNY | 0.12% |
| 2017 FY | -319.93 Million CNY | -37.26% |
| 2016 FY | -233.07 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -6908.406% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 992.333% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 305129.542% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 6112.866% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -95135.613% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 58685.227% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -8170.326% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 7177.87% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 4902.279% |
| SSY Group Limited | 1.71 Billion HKD | 1158.11% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -244946.033% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 5473.058% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 135.565% |